CV9202 is a combined mix of mRNA molecules coding for six antigens overexpressed in lung cancers, made to induce an immune response against the tumour. Ingmar Hoerr, co-founder and CEO of CureVac GmbH commented: This collaboration is incredibly relevant for CureVac because, as a biotech business, we depend on collaboration with solid partners for the scientific advancement and commercialisation of our substances. Cancers immunotherapy represents one of the primary innovations in tumor treatment of recent years and we are delighted to right now be dealing with Boehringer Ingelheim. The out-licensing and clinical advancement of our promising therapeutic vaccine CV9202 represents the logical next thing in developing this novel treatment for cancer tumor sufferers and the significant dedication from Boehringer Ingelheim underscores the relevance of the mRNA technology.Related StoriesGetting right nourishment throughout life can help protect against osteoporosis in old ageDifferences in supplement D status may account for disparities in breast cancer survival ratesNew dental device that creates more powerful bonds for fillings receives FDA clearanceResearchers analyzed data from 913 patients enrolled in the Calcium Polyp Avoidance Study, a randomized, double-blind, placebo-controlled trial – meaning that neither the patient nor the those following them knew which treatment these were receiving. Sufferers took either a 1200 mg calcium supplement or a placebo and experienced a follow-up colonoscopy one and four years after searching for the trial.